Reply to Zaragori et al.: “Is IDH mutation status associated with 18F-FDopa PET uptake”

We thank Zaragori et al. for reading and commenting on our article regarding the lack of correlation between 3,4‑dihydroxy‑6‑[18F]‑fluoro-L‑phenylalanine (F-DOPA) uptake parameters and IDH mutation status and 1p/19q co-deletion in glioma. These authors had initially suggested that the presence of IDH mutation is associated with higher F-DOPA uptake in a cohort of diffuse grade II and grade III gliomas. In a later study comprising a mixed population of 58 newly diagnosed glioma and glioblastoma patients, the same group did not confirm their previous observation, showing similar static F-DOPA uptake parameters between tumors with different molecular markers